Trial | number | Onset to arterial access window | Age limits | Mean age enrolled | NIHSS limits | Median NIHSS enrolled | Proportion treated with alteplase (%) | Device | Vessel occlusion | Imaging selection | General anaesthesia (%) | Onset to arterial access (min) | Successful revascularisation (mTICI 2b/3) (%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IMS 3 | 656 | 6 | 18–82 | 69 | ≥10 (or 8–9 if occlusion) | 17 | 100 | Any approved | Not assessed | Non-contrast CT | 35 | 208 | 41 |
MR CLEAN | 500 | 6 | ≥18 | 65.8 | ≥2 | 18 | 89 | Any approved (82% stent retriever) | ICA/M1/M2/A1/A2 | CT + CTA | 38 | 260 | 59 |
ESCAPE | 316 | 12 (84% <6 h) | ≥18 | 69.5 | ≥6 | 17 | 72 | Any approved (79% stent retriever, 61% Solitaire) | ICA/M1/M1 equivalent (all M2s) | CT+CTA/mCTA collateral scoring +/−CTP | 9 | 200 | 76 |
EXTEND-IA | 70 | 6 | ≥18 | 69.4 | No limits | 15 | 100 | Solitaire | ICA/M1/M2 | CT+CTA +CTP | 36 | 210 | 86 |
SWIFT PRIME | 196 | 6 | 18–80 (initially 18–85) | 65.7 | ≥8 | 17 | 100 | Solitaire | ICA/M1 | CT+CTA +/−CTP or MRI | 37 | 224 | 88 |
REVASCAT | 206 | 8 (90%<6 h) | 18–80† | 66.5 | ≥6 | 17 | 73 | Solitaire | ICA/M1 | CT+CTA +/−CTP | 6.7 | 269 | 66 |
CTA, CT angiography; CTP, CT perfusion; ICA, internal carotid artery; mCTA, multidetector CTA; NIHSS, National Institutes of Health Stroke Scale.